Document is current
Any future updates will be listed below
-
Authors
Liebrand, Luka C.
Karkalousos, Dimitrios
Poirion, Émilie
Emmer, Bart J.
Roosendaal, Stefan D.
Marquering, Henk A.
Majoie, Charles B. L. M.
Savatovsky, Julien
Caan, Matthan W. A. https://orcid.org/0000-0002-5162-8880
-
Funding
Funding for this research was provided by:
Health~Holland
- License Information
-
More Information
Article History
Received: 30 April 2024
Revised: 7 August 2024
Accepted: 8 August 2024
First Online: 30 August 2024
Declarations
:
: B.J. Emmer received funds from Healthcare Evaluation Netherlands, Health Holland. (unrelated to this project; all paid to institution). C.B.L.M. Majoie received funds from: CVON/Dutch Heart Foundation, European Commission, Healthcare Evaluation Netherlands, TWIN Foundation and Stryker (unrelated to this project; all paid to institution. H.A. Marquering, C.B.L.M. Majoie and M.W.A. Caan are shareholders of Nicolab International Ltd. H.A. Marquering is a shareholder of TrianecT B.V. (unrelated to this project; all paid individually) J. Savatovsky received funds for travel costs and lecture fees: Koninklijke Philips N.V., Canon Inc., and Bayer AG. Julien Savatovsky is a shareholder of Chipiron, Guerbet, and GeodAIsics.
: The research was approved by the Rothschild Foundation Hospital review board – IRB 00012801- under the study number CE_20210928_2_JSY.
